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SCIENTIFIC OPINION 
Scientific Opinion related to a notification from the Oenological Products 
and Practices International Association (OENOPPIA) on lysozyme from 
hen’s egg to be used in the manufacture of wine as an anti-microbial 
stabilizer/additive pursuant to Article 6, paragraph 11 of Directive 
2000/13/EC – for permanent exemption from labelling1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to deliver a scientific opinion related to a notification from the Oenological Products and 
Practices International Association (OENOPPIA) on lysozyme from hen‟s egg used in the manufacture of wine as 
an anti-microbial stabilizer/additive pursuant to Article 6, paragraph 11 of Directive 2000/13/EC – 
for permanent exemption from labelling. Allergic sensitisation against lysozyme is common among egg allergic 
individuals. In winemaking, lysozyme is used for the control of lactic acid bacteria, and it is considered essential 
to obtain consistent and high quality. Lysozyme can be used at different stages of wine production and at 
different doses, and no steps are taken specifically to remove lysozyme from wine. In the studies provided by the 
applicant, lysozyme was detected in some of the lysozyme-treated wines under the proposed conditions of use. 
The applicant estimated lysozyme content in white wines with and without bentonite treatment, and in red wines 
without bentonite treatment. Residual amounts of lysozyme considered sufficient to trigger allergic reactions in 
susceptible individuals have been demonstrated in wines treated with lysozyme, and a number of clinical reports 
(including one double-blind placebo-controlled food challenge with lysozyme) described clinical allergic 
reactions to lysozyme. The Panel concludes that wines treated with lysozyme may trigger adverse allergic 
reactions in susceptible individuals under the conditions of use proposed by the applicant. © European Food 
Safety Authority, 2011 
KEY WORDS 
Wine, anti-microbial stabilizer, lysozyme, food allergy. 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2011-00833, adopted on 15 September 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on Allergy: Pagona Lagiou, Martinus 
Løvik, Rosangela Marchelli, Martin Stern, Stephan Strobel, Hendrik van Loveren, Jean Michel Wal for the preparatory 
work on this scientific opinion. 
 
Lysozyme in wine 
 
 
2 EFSA Journal 2011;9(10):2386 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver a scientific opinion related to a notification from Oenological 
Products and Practices International Association (OENOPPIA) on lysozyme from hen‟s egg used in 
the manufacture of wine as an anti-microbial stabilizer/additive pursuant to Article 6, paragraph 11 of 
Directive 2000/13/EC – for permanent exemption from labelling. 
Prevalence of allergy to egg proteins has been reported to be around 0.3 % in adults. Taking into 
account that egg allergic individuals can react to lysozyme and lysozyme-containing foods, it is 
appropriate for the Panel to assess the likelihood of adverse reactions in allergic individuals 
consuming products where lysozyme has been added during the manufacturing process. 
In winemaking, lysozyme is used for the control of lactic acid bacteria. Lysozyme is allowed for use 
in food manufacturing (cheese and wine) in EU countries, and must follow purity specifications set 
forth in European legislation. The purity of only one commercial product was described in the 
application.  
Lysozyme can be used at different stages of wine production and at different doses, and no steps are 
taken specifically to remove lysozyme from wine. In the studies provided by the applicant, lysozyme 
was detected in some of the lysozyme-treated wines under the proposed conditions of use.  
The applicant stated that lysozyme is the weakest allergen among the four major egg white proteins 
and indicated a frequency of sensitisation to lysozyme among egg allergic subjects of 15 %, as 
compared to 53 % for ovotransferrin and 32 % for ovomucoid and ovalbumin. The Panel notes that 
IgE anti-lysozyme antibodies as markers of sensitisation have been found more often in other studies 
e.g. in 35 %, 53 %, and 100 % of egg allergic consumers.  
The applicant cited two human studies in egg-allergic individuals undergoing skin prick testing with 
lysozyme-treated wines. The Panel notes that the results from these studies are consistent with the 
analytical findings of significant residual amounts of lysozyme in treated wines but provide no 
information about the clinical reactivity of egg-allergic individuals to wines treated with lysozyme 
when consumed orally. 
The applicant acknowledged that lysozyme residues are present in lysozyme-treated wines and that 
lysozyme is a sensitizer. However, the applicant proposed that oral consumption of lysozyme may not 
elicit clinical allergic reactions in egg-allergic individuals. The Panel notes that reports (including one 
double-blind placebo-controlled food challenge, DBPCFC) of allergic reactions to lysozyme and 
lysozyme-containing foods among egg-allergic individuals are available in the literature, and that 
results from a clinical study on lysozyme-containing cheese do not allow conclusions about the safety 
of lysozyme consumption in clinically egg allergic individuals.   
The Panel took into account that allergic sensitisation to lysozyme is common among egg allergic 
individuals, that residual amounts of lysozyme considered sufficient to trigger allergic reactions in 
susceptible individuals have been demonstrated in wines treated with lysozyme, and that a number of 
clinical reports (including one DBPCFC with lysozyme) described clinical allergic reactions to 
lysozyme. 
The Panel concludes that wines treated with lysozyme may trigger adverse allergic reactions in 
susceptible individuals under the conditions of use proposed by the applicant. 
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BACKGROUND 
Article 6, paragraph 11 of Directive 2000/13/EC
4
 establishes the cases and conditions for amending 
Annex IIIa to that Directive, which includes a list of food ingredients or substances known as likely to 
trigger allergic reactions in sensitive individuals. It also sets up a procedure for exempting from 
labelling, under certain conditions, derivatives of these ingredients. 
Pursuant to the procedure referred to above, a list of ingredients or substances derived from 
ingredients listed in Annex IIIa has been adopted by the Commission and is included in the Annex to 
Commission Directive 2007/68/EC
5
 of 27 November 2007, amending Annex IIIa to Directive 
2000/13/EC of the European Parliament and of the Council as regards certain food ingredients. 
Applicants who are seeking the exclusion of a given product from Annex IIIa have to submit a 
request, completed with the results of relevant scientific studies. 
Therefore, in the context of the permanent labelling exemption procedure, the European Food Safety 
Authority is asked to provide scientific opinions on submissions in accordance with the present terms 
of reference. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION  
In accordance with Article 29(1)(a) of Regulation (EC) N° 178/2002, the European Commission 
requests the European Food Safety Authority to evaluate the scientific data submitted by the 
Oenological Products and Practices International Association (OENOPPIA) in the framework of the 
procedure laid down in Article 6, paragraph 11 of Directive 2000/13/EC. On the basis of that 
evaluation, EFSA is requested to issue an opinion on the information provided, and particularly to 
consider the likelihood of adverse reactions triggered in susceptible individuals by the consumption of 
the following ingredients/substances used under the conditions specified by the applicant: lysozyme 
from hen‟s egg to be used in the manufacture of wine as an anti-microbial stabilizer/additive. 
                                                     
4  Directive 2000/13/EC of the European Parliament and of the Council of 20 March 2000 on the approximation of the laws 
of the Member States relating to the labelling, presentation and advertising of foodstuffs. OJ L 109, 6.5.2000, p. 29–42. 
5  Commission Directive 2007/68/EC of 27 November 2007 amending Annex IIIa to Directive 2000/13/EC of the European 
Parliament and of the Council as regards certain food ingredients. OJ L 310, 28.11.2007, p. 11–14.  
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ASSESSMENT  
Prevalence of allergy to egg proteins has been reported to be around 0.3 % in adults (EFSA, 2004; 
Sampson, 2004; Sicherer and Sampson, 2010; Vierk et al., 2007). Taking into account that egg 
allergic individuals can react to lysozyme and lysozyme-containing foods (EFSA, 2005), it is 
appropriate for the Panel to assess the likelihood of adverse reactions in allergic individuals 
consuming products where lysozyme has been added during the manufacturing process. 
Dossiers submitted by Deutscher Weinbauverband (DWV) and the Office National Interprofessionel 
des Fruits, des Légumes, des Vins et de l‟Horticulture (VINIFLHOR), and by the Winemakers‟ 
Federation of Australia (WFA) and the Australian Wine Research Institute (AWRI), to the European 
Commission pursuant to Article 6, Paragraph 11 of Directive 2000/13/EC as amended by Directive 
2003/89/EC6 for permanent exemption from labelling were the basis for earlier assessments of egg 
products and albumin (egg white), with or without lysozyme, used as fining agents in wine by the 
Panel on Dietetic Products, Nutrition and Allergies (NDA) (EFSA, 2007a, 2007b). A dossier 
submitted by the Association of Manufacturers of Natural Animal-derived Food Enzymes (AMAFE) 
was the basis for an early assessment of egg lysozyme used as additive in food (EFSA, 2005). 
The present opinion is based on a dossier from the Oenological Products and Practices International 
Association (OENOPPIA), with an application for permanent exemption. This application refers to 
the use of lysozyme from hen‟s egg in the manufacture of wine as an anti-microbial 
stabilizer/additive.  
1. Characterisation of the fining agent  
The common name is „egg white lysozyme‟, the Commission on Enzymes of the International Union 
of Biochemistry‟s systematic name is “peptidoglycan N-acetylmuramoylhydrolase”, its systematic 
number is EC No. 3.2.1.17, and its Chemical Abstract Service (CAS) number is 9001-63-2. In the 
official allergen nomenclature, egg lysozyme is Gal d 4. The E number of lysozyme is E1105. 
Lysozyme is a non-glycosylated antimicrobial protein consisting of 129 amino acids, and has a 
molecular weight of about 14.4 kD. Lysozyme was the first protein to be sequenced and to have its 
three-dimensional structure completely analysed. Lysozyme from different sources shows only small 
variations in amino acid sequence and three-dimensional structure. No IgE binding epitope has yet 
been defined on lysozyme. 
In winemaking, lysozyme is used for the control of lactic acid bacteria, and according to the applicant 
it is considered essential in certain situations to obtain consistent and high quality. Lysozyme is 
allowed for use in food manufacturing (cheese and wine) in EU countries, and must follow purity 
specifications set forth in European legislation. Lysozyme is extracted from egg white, where it 
constitutes approximately 0.3 % of the mass and 3.5 % of the proteins. 
Lysozyme is produced under good manufacturing practice (GMP) conditions by the applicant. 
According to the applicant, the protein purity of their product is controlled by SDA-PAGE and HPLC. 
References are given to a report comparing the purity of the (industrial) lysozyme with a standard of 
“highly purified” lysozyme (Sigma-Aldrich ref. L6876). In SDS-PAGE, lysozyme appears “almost 
pure”, with only faint traces of avidin and of a lysozyme dimer, while gallin, conalbumin, ovalbumin, 
or ovomucoid were not detected. According to the applicant, avidin is not considered to be an egg 
allergen (Cooper et al., 2009). HPLC analysis shows that at a concentration of 10 g/L, contaminating 
egg proteins (conalbumin, ovomucoids and ovalbumin, the major egg allergens according to the 
                                                     
6  Directive 2003/89/EC of the European Parliament and of the Council of 10 November 2003 amending Directive 
2000/13/EC as regards indication of the ingredients present in foodstuffs. OJ L 308, 25.11.2003, p. 15–18. 
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applicant) have been reduced to undetectable levels at a limit of detection (LOD) of 10 mg/L for 
avidin and conalbumin, and 20 mg/L for ovalbumin.  
The Panel notes that the purity of only one commercial product was described in the application.  
2. Conditions of use 
Lysozyme is used as an alternative to, or in combination with, sulphites to control growth of lactic 
acid bacteria without inhibiting the yeasts responsible for alcoholic fermentation. Specifically, the 
applicant listed four major applications for lysozyme: a) preventive control of the onset of malo-lactic 
fermentation (early addition of 100–150 mg/L); b) total inhibition of malo-lactic fermentation (at a 
dose of 500 mg/L); c) protection of wine during sub-optimal alcoholic fermentation (at doses of 
250-300 mg/L); d) stabilization of wine after malo-lactic fermentation (at doses of 250-300 mg/L).  
The Panel notes that lysozyme can be used at different stages of wine production and at different 
doses, and that no steps are taken specifically to remove lysozyme from wine. 
3. Analysis of residual allergens in wine 
In published literature cited by the applicant (Weber et al., 2007; 2009), residual amounts of lysozyme 
were detected in four German wines experimentally treated with lysozyme and fined with bentonite at 
the level of detection of the competitive ELISA used (LOD=0.001 mg/L), corresponding to 0.01 mg/L 
considering dilution. One wine had significantly higher levels of lysozyme (estimated at 0.06 mg/L). 
Without bentonite fining, the levels of lysozyme detected in wines by HPLC analysis were 
significantly higher (i.e. up to 183 mg/L and 327 mg/L in white wines treated with 250 mg/L and 
500 mg/L of lysozyme, respectively, and up to 27 mg/L and 38 mg/L in red wines treated with 
250 mg/L and 500 mg/L of lysozyme, respectively). The authors concluded that allergic reactions to 
lysozyme-treated wine cannot be excluded and that lysozyme-treated wine could possibly trigger 
allergic reactions in susceptible individuals after moderate wine consumption (0.1-0.7 L). The Panel 
notes that bentonite treatment is not mandatory in the manufacture of wine. 
In a new study commissioned by the applicant, lysozyme residues were determined in 29 commercial 
lysozyme-treated wines (three white, two rosé, and 24 red wines) from five countries (vintages 
2004-2010), with or without bentonite and metatartaric acid fining (Restani, 2011, unpublished). 
When examined unconcentrated by immunoblotting with an anti-lysozyme antibody, two wines 
showed lysozyme residues of 8.6 mg/L and 2.6 mg/L, respectively, which were above the reported 
limit of detection/quantification of 0.49 mg/L. The positivity for lysozyme was confirmed by HPLC 
(LOD=0.18 mg/L), by a microbiological plating method, and by the use of an anti-egg white antibody 
in immunoblotting (LOD=0.25 mg/L). When concentrated five times, three more wines showed 
residues of lysozyme close to the detection limit, suggesting an (unconcentrated) level of 0.1 mg/L 
lysozyme in these wines.  
The Panel notes that lysozyme was detected in some of the lysozyme-treated wines under the 
conditions of use proposed by the applicant.  
4. Estimated level of exposure 
On the basis of the data reported by Weber et al. (2007; 2009), the applicant estimated lysozyme 
content in white wines with (0.06 mg/L) and without (200-330 mg/L) bentonite treatment, and in red 
wines without bentonite treatment (30-40 mg/L). The applicant provided exposure estimates to 
lysozyme from cheese and wine for 19 European countries, assuming a mean lysozyme content of 
250 mg/kg in cheese and of 40 mg/L in wine. The Panel notes that intake on a single occasion may be 
more relevant regarding food allergic reactions than average daily or yearly intake, that no estimations 
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of lysozyme intakes on a single occasion have been provided, and that no generally applicable 
threshold levels of intake have been defined for food allergens (NDA, 2004). 
5. Evidence of non-allergenicity 
5.1. History of non-allergenicity of the product 
The applicant stated that lysozyme is the weakest allergen among the four major egg white proteins 
(Bianchi, 1982; Hoffman, 1983; JECFA, 1993) and indicated a frequency of sensitisation to lysozyme 
among egg allergic subjects of 15 %, as compared to 53 % for ovotransferrin and 32 % for ovomucoid 
and ovalbumin (Poulsen et al., 2001). The Panel notes that IgE anti-lysozyme antibodies as markers of 
sensitisation have been found more often in other studies e.g. in 35 %, 53 %, and 100 % of egg 
allergic consumers (Fremont et al., 1997; Holen and Elsayed, 1990; Suzuki et al., 2010).  
The applicant cited two human studies in egg-allergic individuals undergoing skin prick testing with 
lysozyme-treated wines.   
One publication (Kirschner et al., 2009) reported on five patients allergic to egg (four with a positive 
and one with a negative skin prick test to lysozyme), three of whom underwent skin prick testing with 
two lysozyme-treated wines. Two patients reacted to the lysozyme-treated wines. However, one of 
these two patients also reacted to the corresponding control (unfined) wines. Different from what is 
stated in the application, this publication does not report on a double-blind placebo-controlled food 
challenge (DBPCFC) using lysozyme-treated wines. The Panel considers that these results are 
consistent with the analytical findings of significant residual amounts of lysozyme in treated wines 
but provide no information about the clinical reactivity of egg-allergic individuals to wines treated 
with lysozyme when consumed orally. 
In the second publication (Weber et al., 2009), two out of three egg-allergic patients showed 
significant skin prick reactions to lysozyme (250 and 500 mg/L) treated red wine (unconcentrated, no 
bentonite treatment) and slight reactions to bentonite-treated but (100x) concentrated white and red 
wines (the same wines unfined were used as control). No oral challenge was performed. The Panel 
notes that these results are consistent with the analytical findings of significant residual amounts of 
lysozyme in treated wines but provide no information about the clinical reactivity of egg-allergic 
individuals to wines treated with lysozyme when consumed orally.   
The applicant acknowledges that lysozyme residues are present in lysozyme-treated wines and that 
lysozyme is a sensitizer. However, the applicant proposes that oral consumption of lysozyme may not 
elicit clinical allergic reactions in egg-allergic individuals. Accordingly, a literature search was 
performed by the applicant to identify possible cases of allergic reactions to lysozyme or 
lysozyme-containing foods (not limited to wine) in egg-allergic individuals. The strategy used and the 
database(s) searched were not described in the application. The applicant‟s search identified two 
publications which describe possible allergic reactions to lysozyme (Fremont et al., 1997; Malmheden 
Yman, 2004).  
One publication reported on a DBPCFC study (Fremont et al., 1997) in which two out of six egg 
allergic children showed clinical signs upon oral challenge with lysozyme. One additional patient had 
a labial challenge with one drop of lysozyme solution (1 mg/mL) and reacted. The applicant argues 
that insufficiencies in reporting (e.g. regarding the purity of the lysozyme preparations and the doses 
used) may limit the conclusions which can be drawn from this study with respect to the allergenicity 
of lysozyme.  
The second publication described five cases of serious allergic reactions to lysozyme-treated cheese 
that were reported to the Swedish register along with 16 other cases of clinical reactions to egg 
(Malmheden Yman, 2004). The applicant stated that insufficiencies in reporting (e.g. presence of 
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other allergens in cheese, lack of data on lysozyme concentrations in the cheese samples) may limit 
the conclusions which can be drawn from this publication with respect to the allergenicity of 
lysozyme. The Panel is aware of a number of other case reports on allergic reactions supposedly 
triggered by lysozyme in cheese and in pharmaceutical products (e.g. Artesani et al., 2008; Ledesma 
Benitez et al., 2007; Perez-Calderon et al., 2007; Pichler and Campi, 1992).  
The applicant also cites a single blind, placebo-controlled study (Iaconelli et al., 2008) in which 20 
“egg allergic” subjects (17 of which had a radioallergosorbent test (RAST) positive for lysozyme 
and/or ovomucoid and ovalbumin) were challenged with up to 60 g of Grana Padano cheese 
containing 155 mg/kg lysozyme. No symptoms were triggered by the cheese in any of the challenged 
subjects. The Panel notes that apart from the statement that the “egg allergic” subjects had never 
experienced any gastrointestinal or respiratory symptoms on exposure to hen‟s egg, no clinical 
characterisation or verification of clinical egg allergy was provided besides seropositivity. The Panel 
considers that this study does not allow conclusions to be drawn regarding the safety of lysozyme 
consumption in clinically egg allergic individuals.  
The Panel notes that reports (including one DBPCFC) of allergic reactions to lysozyme and 
lysozyme-containing foods among egg-allergic individuals are available in the literature, and that 
results from one study using lysozyme-containing cheese are inconclusive with respect to the 
likelihood of clinical allergic reactions to oral consumption of lysozyme in egg-allergic subjects due 
to the inadequate clinical characterisation of the study population. 
The Panel further notes that reactions to wine, including allergic reactions, are well documented 
(Armentia, 2008; Vally and Thompson, 2003). Since consumers and health professionals may be 
unaware that egg-derived products including lysozyme are used in the winemaking process, allergic 
reactions to lysozyme have generally not been considered following reactions to wine and therefore 
underreporting of reactions caused by lysozyme after ingestion of wines may have occurred.  
5.2. Animal studies 
No data on animal studies were provided in the application. 
5.3. Clinical studies 
No clinical studies were provided by the applicant besides those described in section 5.1.   
CONCLUSIONS 
The Panel took into account that allergic sensitisation to lysozyme is common among egg allergic 
individuals, that residual amounts of lysozyme considered sufficient to trigger allergic reactions in 
susceptible individuals have been demonstrated in wines treated with lysozyme, and that a number of 
clinical reports (including one DBPCFC with lysozyme) described clinical allergic reactions to 
lysozyme in egg-allergic individuals. 
The Panel concludes that wines treated with lysozyme may trigger adverse allergic reactions in 
susceptible individuals under the conditions of use proposed by the applicant. 
DOCUMENTATION PROVIDED TO EFSA 
Dossier submitted by OENOPPIA to the European Commission pursuant to Article 6, paragraph 11 of 
Directive 2000/13/EC as amended by Directive 2003/89/EC, in June 2011. 
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GLOSSARY / ABBREVIATIONS 
AMAFE Association of Manufacturers of Natural Animal-derived Food Enzymes 
AWRI  Australian Wine Research Institute 
CAS  Chemical Abstract Service  
DBPCFC Double-blind placebo-controlled food challenge 
DWV  Deutscher Weinbauverband 
ELISA  Enzyme-Linked Immunosorbent Assay 
GMP  Good Manufacturing Practice  
HPLC  High-performance liquid chromatography  
LOD  Limit of detection  
OENOPPIA Oenological Products and Practices International Association  
RAST  Radioallergosorbent test  
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
VINIFLHOR Office National Interprofessionel des Fruits, des Légumes, des Vins et de 
l‟Horticulture 
WFA  Winemakers‟ Federation of Australia  
